EP2782894A4 - PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERIUM-ENRICHED PERILLYL ALCOHOL, ISOPERILLYL ALCOHOL AND DERIVATIVES THEREOF - Google Patents

PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERIUM-ENRICHED PERILLYL ALCOHOL, ISOPERILLYL ALCOHOL AND DERIVATIVES THEREOF

Info

Publication number
EP2782894A4
EP2782894A4 EP12867815.8A EP12867815A EP2782894A4 EP 2782894 A4 EP2782894 A4 EP 2782894A4 EP 12867815 A EP12867815 A EP 12867815A EP 2782894 A4 EP2782894 A4 EP 2782894A4
Authority
EP
European Patent Office
Prior art keywords
deuterium
enriched
derivatives
pharmaceutical compositions
perilyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12867815.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2782894A2 (en
Inventor
Thomas Chen
Daniel Levin
Satish Pupalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neonc Technologies Inc
Original Assignee
Neonc Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/566,731 external-priority patent/US8916545B2/en
Application filed by Neonc Technologies Inc filed Critical Neonc Technologies Inc
Publication of EP2782894A2 publication Critical patent/EP2782894A2/en
Publication of EP2782894A4 publication Critical patent/EP2782894A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05—Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP12867815.8A 2011-11-21 2012-11-21 PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERIUM-ENRICHED PERILLYL ALCOHOL, ISOPERILLYL ALCOHOL AND DERIVATIVES THEREOF Withdrawn EP2782894A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161562105P 2011-11-21 2011-11-21
US13/566,731 US8916545B2 (en) 2010-08-27 2012-08-03 Pharmaceutical compositions comprising POH derivatives
PCT/US2012/066379 WO2013119304A2 (en) 2011-11-21 2012-11-21 Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof

Publications (2)

Publication Number Publication Date
EP2782894A2 EP2782894A2 (en) 2014-10-01
EP2782894A4 true EP2782894A4 (en) 2015-03-11

Family

ID=48948152

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12867815.8A Withdrawn EP2782894A4 (en) 2011-11-21 2012-11-21 PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERIUM-ENRICHED PERILLYL ALCOHOL, ISOPERILLYL ALCOHOL AND DERIVATIVES THEREOF

Country Status (8)

Country Link
EP (1) EP2782894A4 (enExample)
JP (2) JP2015502352A (enExample)
KR (1) KR20150000469A (enExample)
CN (1) CN103946202A (enExample)
BR (1) BR112014012180A2 (enExample)
CA (1) CA2856403A1 (enExample)
HK (1) HK1201253A1 (enExample)
WO (1) WO2013119304A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945335B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏胺类化合物及其制备和应用
CN104945334B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏醇衍生物及其制备和应用
CN104945333B (zh) * 2014-03-27 2018-02-02 沈阳药科大学 紫苏醇类似物及其制备和应用
CN104945336B (zh) * 2014-03-27 2018-02-16 沈阳药科大学 紫苏酸甲酯含氮衍生物及其制备和应用
WO2019157195A1 (en) 2018-02-08 2019-08-15 Neonc Technologies, Inc Methods of permeabilizing the blood brain barrier
CN116789530B (zh) * 2023-05-16 2025-12-19 杭州师范大学 一种紫苏醇酚类衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091198A1 (en) * 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272441A (en) * 1980-03-13 1981-06-09 Fmc Corporation Preparation of carbamates
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
WO2003057193A1 (en) * 2001-12-11 2003-07-17 Dor Biopharma, Inc. Monoterpene compositions and uses thereof
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
ATE405259T1 (de) * 2004-06-23 2008-09-15 Robert F Hofmann Verwendung einer gezielten oxidativen therapeutischen formulierung bei der behandlung von verbrennungen
WO2007053189A2 (en) 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
EP2081565A2 (en) * 2006-10-13 2009-07-29 Reliance Life Sciences Pvt., Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
CN105078973B (zh) * 2010-08-27 2020-10-09 尼昂克技术公司 包含poh衍生物的药物组合物
CN101979378B (zh) * 2010-10-13 2012-06-27 中国科学院上海有机化学研究所 一种手性γ-内酰胺化合物的合成方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091198A1 (en) * 2009-02-06 2010-08-12 University Of Southern California Therapeutic compositions comprising monoterpenes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2013119304A2 *
TUNG R: "The Development of Deuterium-Containing Drugs", INNOVATIONS IN PHARMACEUTICAL TECHNOLOGY, SAMEDAN LTD, GB, no. 32, 1 March 2010 (2010-03-01), pages 24 - 26,28, XP009148260, ISSN: 1471-7204 *

Also Published As

Publication number Publication date
BR112014012180A2 (pt) 2017-05-30
CN103946202A (zh) 2014-07-23
JP2018035148A (ja) 2018-03-08
WO2013119304A3 (en) 2013-10-03
KR20150000469A (ko) 2015-01-02
JP2015502352A (ja) 2015-01-22
CA2856403A1 (en) 2013-08-15
EP2782894A2 (en) 2014-10-01
WO2013119304A2 (en) 2013-08-15
HK1201253A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
EP2609064A4 (en) PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES
EP2746283A4 (en) PYRIMIDOPYRIMIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES
EP2827866A4 (en) PHARMACEUTICAL COMPOSITIONS WITH BENZYL ALCOHOL
EP2616076A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2758052A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2705181A4 (en) PHARMACEUTICAL COMBINATION COMPOSITIONS AND ITS USE
SMT201600338B (it) Formulazioni farmaceutiche comprendenti derivati di1-(beta-d- glucopiranosil)- 2-tienilmetilbenzene come inibitori di sglt
EP2535339A4 (en) POLYMORPHES OF DASATINIB, METHOD OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS THEREOF
DK2632493T3 (da) Lægemiddelindgivelsessammensætninger
DK3181122T3 (da) Farmaceutisk dasatinib-sammensætning
EP2771020A4 (en) N-ACID DIPEPTIDE DERIVATIVES AND THEIR USE
EP2562172A4 (en) SPHAELACTON DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION AND THEIR USE
EP2616053A4 (en) PHARMACEUTICAL COMPOSITIONS FROM CURCUMIN
BR112013012476A2 (pt) formulações farmacêuticas contendo corticosteróides para administração tópica
EP2773346A4 (en) PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES
CO7061076A2 (es) Composición farmacéutica que contiene un derivado de dihidroquinazolina antiviralmente activo
EP2827867A4 (en) PHARMACEUTICAL COMPOSITIONS WITH GLYCERINESTERS
BRPI0921654A2 (pt) formulação farmacêutica
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
CO6940426A2 (es) Formulaciones farmacéuticas
EP2815752A4 (en) ORAL PHARMACEUTICAL COMPOSITION
EP2775831A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP2782894A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERIUM-ENRICHED PERILLYL ALCOHOL, ISOPERILLYL ALCOHOL AND DERIVATIVES THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140509

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150205

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4015 20060101ALI20150130BHEP

Ipc: A61K 31/4188 20060101ALI20150130BHEP

Ipc: A61K 31/05 20060101ALI20150130BHEP

Ipc: A61K 31/415 20060101ALI20150130BHEP

Ipc: C07C 35/18 20060101AFI20150130BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201253

Country of ref document: HK

17Q First examination report despatched

Effective date: 20160829

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180602

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201253

Country of ref document: HK